Progesterone Receptor antibody (pSer294)

Catalog No. ABIN361518

This anti-Progesterone Receptor antibody is a Mouse Monoclonal antibody detecting Progesterone Receptor in WB and IHC. Suitable for Human.

Quick Overview for Progesterone Receptor antibody (pSer294) (ABIN361518)

Target: Progesterone Receptor (PGR)

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This Progesterone Receptor antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Clone: 608

Product Details anti-Progesterone Receptor Antibody

Binding Specificity: pSer294

Specificity: Specific for the ~90k PR-A isoform and the ~120k PR-B isoform phosphorylated at Ser294. Immunolabeling is blocked by the phosphopeptide used as the antigen but not by the corresponding dephosphopeptide.

Cross-Reactivity: Human

Predicted Reactivity: non-human primates

Purification: Protein G purified culture supernatant

Immunogen: Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser294 conjugated to KLH

Isotype: IgG1

Application Details

Application Notes: Recommended Dilution: WB: 1:1000 IHC (frozen sections, unpublished observations): 1:1000 Quality Control: Western blots performed on each lot.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: 100 μL in 10 mM HEPES (  pH 7.5), 150 mM NaCl, 100 μg per ml BSA and 50 % glycerol.

Storage: -20 °C

Target Details for Progesterone Receptor

Target: Progesterone Receptor (PGR)

Alternative Name: PGR

Background: There is accumulating evidence to suggest that progesterone plays an essential role in the regulation of growth and differentiation of mammary glands and thus may play a key role in breast cancer (Edwards, 2005). The biological response to progesterone is mediated by two distinct forms of the human progesterone receptor (PR-A and PR-B forms). In most cell contexts, the B form functions as a transcriptional activator, whereas the A form functions as a transcriptional inhibitor of steroid hormones (Attia et al., 2000, Lin et al., 2003). Recently it has been demonstrated that there is differential hormone dependent regulation of the phosphorylation of the A and B forms of the receptor (Clemm et al., 2000) . Treatment of T47D breast cancer cells with progestin agonist increases the phosphorylation of Ser190 and Ser294 with different kinetics. These phosphorylation events may differentially affect the transcriptional activity of the receptor. Anti-Phospho Ser294 Progesterone Receptor Western blot of whole cell T47D lysate prepared from cells that had been incubated in the presence of the synthetic progestin agonist R5020 (500 nM) showing specific immunolabeling of the ~90k PR-A isoform and the ~120 PR-B isoform of the progesterone receptor phosphorylated at Ser294. The immunolabeling is blocked by the phosphopeptide used as the antigen (not shown).

Molecular Weight: 90/120 kDa

Gene ID: 5241

UniProt: P06401

Pathways: Nuclear Receptor Transcription Pathway, Intracellular Steroid Hormone Receptor Signaling Pathway, Steroid Hormone Mediated Signaling Pathway, Smooth Muscle Cell Migration